Heart Failure Clinical Trial
— VICTORID-HFOfficial title:
Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency
The goal of this randomized, controlled, open-label, interventional study is to evaluate whether, in patients with heart failure (HF) and iron deficiency (ID), the administration of vitamin D in combination with sucrosomial iron is as effective as intravenous ferric carboxymaltose in improving symptoms of HF. The main hypothesis which the study aims to test is the non-inferiority of sucrosomial iron (± vitamin D) compared with FCM treatment, after 24 weeks. Primary endpoint: the performance of the Six-Minute Walking Test, comparing the mean difference from baseline of the distance walked by patients in meters. Participants will be evaluated in outpatient scheduled visits at 6, 12 and 24 weeks, performing blood tests, clinical evaluation, instrumental investigations and recording any adverse events, cardiovascular events, re-hospitalizations and fractures. The study will involve randomization into 3 groups with a 1:1:1 ratio: 1. Control group [standard of care]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and hemoglobin values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID. 2. Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks. 3. Sucrosomial iron and vitamin D group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily + vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks
Status | Not yet recruiting |
Enrollment | 258 |
Est. completion date | October 31, 2025 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: NYHA functional class II-III due to symptomatic chronic HF and all the following: - At least 3 weeks since the last hospitalization or emergency department access for acute HF decompensation. - Optimal drug treatment for HF according to the European Society of Cardiology guidelines determined by the investigator (unless contraindications or treatment not tolerated). - No changes in HF therapy dosage in the previous 2 weeks (except diuretics). - No new HF therapy in the 3 weeks prior to recruitment. - LVEF =45%. - Brain Natriuretic Peptide (BNP) >100 pg/mL and/or NT-proBNP >400 pg/mL at pre-recruitment evaluation. - Evidence of ID defined as ferritin <100 ng/ml or TSAT <20% in case of ferritin levels between 100 and 300 ng/ml. - 25-OH-Vitamin D levels <50 nmol/L. - The subject must be able to complete the 6MWT. - At least 18 years of age. Exclusion Criteria: - Myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke, coronary artery bypass, percutaneous intervention, or major thoracic or cardiac surgery within the previous 2 months. - Clinically relevant (severe) non-corrected valvular heart disease, obstructive cardiomyopathy. - Chronic anemia due to non-correctable causes other than ID and anemia of chronic disease (e.g., hemoglobinopathies, hematologic malignancies, hemolytic anemia). - Anemia due to Vitamin B12 or acid folic deficiency. Recruitment may be re-evaluated at least 6 weeks after the end of vitamin B12 and or folic acid supplementation. - History of acquired iron overload. - Administration of erythropoietin, iron supplementation (either oral or intravenous iron), blood transfusion in the previous 6 weeks or already scheduled for the 3 months after recruitment. - Administration of vitamin D or similar in the 3 months preceding or already scheduled for the 3 months following recruitment. - Severe bone disease. - Active infections, C-reactive protein (CRP) >20 mg/L, clinically significant bleeding, active neoplasm (with exception of basal cell or squamous cell carcinoma of the skin and intraepithelial cervical neoplasia). - Chronic liver disease (including active hepatitis) and/or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x normal limit. - Immunosuppressive therapy or dialysis. - Pregnancy or breastfeeding. - The subject has a known sensitivity to any of the products that will be administered during the study protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Padova |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-inferiority of Six-Minute Walking Test (6MWT) | To evaluate the change from baseline performance of the 6MWT, in the three treatment arms, measuring the distance walked by patients in meters | 24 weeks | |
Secondary | Quality of life (QoL) assessment | To evaluate the change from baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the three treatment arms | 24 weeks | |
Secondary | Cardiovascular and general endpoint 1 | Change from baseline in the NYHA class in the sucrosomial iron + vitamin D group compared with the control group | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 2 | Change from baseline in the NYHA class in the sucrosomial iron + vitamin D group compared the sucrosomial iron group | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 3 | Change from baseline in distance walked at 6MWT in the sucrosomial iron + vitamin D group compared with sucrosomial iron alone | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 4 | Change in the glomerular filtration rate estimated using the CKD-EPI formula. | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 5 | Surviving days out of hospital. | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 6 | Hospitalizations (total, cardiovascular, due to HF). | 12 and 24 weeks | |
Secondary | Cardiovascular and general endpoint 7 | Mortality (total, cardiovascular, due to HF) | 12 and 24 weeks | |
Secondary | Echocardiographic endpoint 1 | Changes in left ventricle ejection fraction [LVEF, Simpson's method] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 2 | Changes in left ventricle end diastolic diameter [LVEDD] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 3 | Changes in left ventricle end systolic diameter [LVESD] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 4 | Changes in left ventricle end diastolic volume [LVEDV] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 5 | Changes in left ventricle end systolic volume [LVESV] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 6 | Changes in Interventricular septal thickness [IVS] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 7 | Changes in left ventricular posterior wall [PW] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 8 | Changes in diastolic function [E/e'] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 9 | Changes in diastolic function [E/A ratio] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 10 | Changes in left atrial volume index [LAVI] compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 11 | Changes in Tricuspid regurgitation [TR] peak velocity compared with baseline in the sucrosomial iron + vitamin D group | 24 weeks | |
Secondary | Echocardiographic endpoint 12 | Changes in left ventricle ejection fraction [LVEF, Simpson's method] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 13 | Changes in left ventricle end diastolic diameter [LVEDD] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 14 | Changes in left ventricle end systolic diameter [LVESD] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 15 | Changes in left ventricle end diastolic volume [LVEDV] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 16 | Changes in left ventricle end systolic volume [LVESV] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 17 | Changes in Interventricular septal thickness [IVS] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 18 | Changes in left ventricular posterior wall [PW] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 19 | Changes in diastolic function parameters [E/A ratio] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 20 | Changes in diastolic function parameters [E/e'] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 21 | Changes in left atrial volume index [LAVI] in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Echocardiographic endpoint 22 | Changes in Tricuspid regurgitation [TR] peak velocity in the sucrosomial iron + vitamin D group compared with the control group | 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 1 | Plasma levels of calcium in the sucrosomial iron + vitamin D group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 2 | Plasma levels of phosphate in the sucrosomial iron + vitamin D group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 3 | Plasma levels of FGF-23 in the sucrosomial iron + vitamin D group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 4 | Plasma levels of calciumin the sucrosomial iron group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 5 | Plasma levels of phosphate in the sucrosomial iron group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 6 | Plasma levels of FGF-23 in the sucrosomial iron group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 7 | Incidence of fractures in the sucrosomial iron + vitamin D group compared with the control group | 12 and 24 weeks | |
Secondary | Calcium-phosphorus metabolism endpoint 8 | Incidence of fractures in the sucrosomial iron group compared with the control group | 12 and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|